USP7Ubiquitin specific peptidase 7 (herpes virus-associated)
Autism Reports / Total Reports
8 / 15Rare Variants / Common Variants
31 / 0Aliases
USP7, HAUSP, TEF1Associated Syndromes
Hao-Fountain Syndrome, ADHD, DD, ID, Hao-Fountain syndrome, Hao-Fountain syndrome, DDChromosome Band
16p13.2Associated Disorders
ADHD, ASD, EPSRelevance to Autism
De novo variants (six multigenic deletions, one nonsense variant) affecting the USP7 gene were identified in seven patients presenting with developmental delay/intellectual disability, with five of these cases having an additional diagnosis of ASD (Hao et al., 2015). Subsequent statistical analysis determined that there was a strong correlation between the seven patients having both a de novo USP7 variant and the expressed phenotype that was likely not due to chance (p<0.0001).
Molecular Function
Hydrolase that deubiquitinates target proteins such as FOXO4, p53/TP53, MDM2, ERCC6, DNMT1, UHRF1, PTEN and DAXX. Together with DAXX, prevents MDM2 self-ubiquitination and enhances the E3 ligase activity of MDM2 towards p53/TP53, thereby promoting p53/TP53 ubiquitination and proteasomal degradation. Deubiquitinates p53/TP53 and MDM2 and strongly stabilizes p53/TP53 even in the presence of excess MDM2, and also induces p53/TP53-dependent cell growth repression and apoptosis. In association with DAXX, is involved in the deubiquitination and translocation of PTEN from the nucleus to the cytoplasm. Involved in cell proliferation during early embryonic development.
External Links
SFARI Genomic Platforms
Reports related to USP7 (15 Reports)
# | Type | Title | Author, Year | Autism Report | Associated Disorders |
---|---|---|---|---|---|
1 | Support | Synaptic, transcriptional and chromatin genes disrupted in autism | De Rubeis S , et al. (2014) | Yes | - |
2 | Support | The contribution of de novo coding mutations to autism spectrum disorder | Iossifov I et al. (2014) | Yes | - |
3 | Primary | USP7 Acts as a Molecular Rheostat to Promote WASH-Dependent Endosomal Protein Recycling and Is Mutated in a Human Neurodevelopmental Disorder | Hao YH , et al. (2015) | Yes | Epilepsy/seizures |
4 | Recent Recommendation | Low load for disruptive mutations in autism genes and their biased transmission | Iossifov I , et al. (2015) | Yes | - |
5 | Support | Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability | Lelieveld SH et al. (2016) | No | - |
6 | Support | A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology | Vissers LE , et al. (2017) | No | - |
7 | Recent Recommendation | Pathogenic variants in USP7 cause a neurodevelopmental disorder with speech delays, altered behavior, and neurologic anomalies | Fountain MD , et al. (2019) | No | ASD, ADHD, epilepsy/seizures |
8 | Support | - | Mahjani B et al. (2021) | Yes | - |
9 | Support | - | Qiao H et al. (2022) | Yes | - |
10 | Support | - | Zhou X et al. (2022) | Yes | - |
11 | Support | - | Zheng H et al. (2022) | No | Autistic behavior |
12 | Support | - | Wang J et al. (2023) | Yes | - |
13 | Support | - | Khaled N Itani et al. (2023) | No | - |
14 | Support | - | Moritz Claudius Wimmer et al. (2024) | No | ASD |
15 | Support | - | Mei Sun et al. (2024) | No | Autistic features |
Rare Variants (31)
Status | Allele Change | Residue Change | Variant Type | Inheritance Pattern | Parental Transmission | Family Type | PubMed ID | Author, Year |
---|---|---|---|---|---|---|---|---|
- | - | copy_number_loss | De novo | - | - | 26365382 | Hao YH , et al. (2015) | |
- | - | copy_number_loss | De novo | - | - | 30679821 | Fountain MD , et al. (2019) | |
c.429C>G | p.Tyr143Ter | stop_gained | De novo | - | - | 26365382 | Hao YH , et al. (2015) | |
c.1041T>G | p.Tyr347Ter | stop_gained | Unknown | - | - | 34615535 | Mahjani B et al. (2021) | |
c.1728T>A | p.Cys576Ter | stop_gained | De novo | - | - | 30679821 | Fountain MD , et al. (2019) | |
c.2823G>T | p.Leu941%3D | synonymous_variant | De novo | - | - | 35982159 | Zhou X et al. (2022) | |
c.2241T>C | p.Gly747= | missense_variant | De novo | - | - | 30679821 | Fountain MD , et al. (2019) | |
c.675G>A | p.Met225Ile | missense_variant | De novo | - | - | 30679821 | Fountain MD , et al. (2019) | |
c.863T>C | p.Leu288Ser | missense_variant | De novo | - | Simplex | 37393044 | Wang J et al. (2023) | |
c.1243A>G | p.Thr415Ala | missense_variant | De novo | - | - | 25363760 | De Rubeis S , et al. (2014) | |
c.1258A>G | p.Lys420Glu | missense_variant | De novo | - | - | 27479843 | Lelieveld SH et al. (2016) | |
c.1033G>A | p.Glu345Lys | missense_variant | De novo | - | - | 30679821 | Fountain MD , et al. (2019) | |
c.1105G>A | p.Gly369Ser | missense_variant | De novo | - | - | 30679821 | Fountain MD , et al. (2019) | |
c.1117C>T | p.Leu373Phe | missense_variant | De novo | - | - | 30679821 | Fountain MD , et al. (2019) | |
c.1384T>G | p.Cys462Gly | missense_variant | De novo | - | - | 30679821 | Fountain MD , et al. (2019) | |
c.2297T>C | p.Ile766Thr | missense_variant | De novo | - | - | 30679821 | Fountain MD , et al. (2019) | |
c.835T>G | p.Leu279Val | missense_variant | De novo | - | Simplex | 36466803 | Zheng H et al. (2022) | |
c.992A>G | p.Tyr331Cys | missense_variant | De novo | - | Simplex | 36466803 | Zheng H et al. (2022) | |
c.3017C>T | p.Pro1006Leu | missense_variant | De novo | - | - | 27479843 | Lelieveld SH et al. (2016) | |
c.3238G>A | p.Asp1080Asn | missense_variant | De novo | - | - | 30679821 | Fountain MD , et al. (2019) | |
c.2697A>C | p.Leu899Phe | missense_variant | De novo | - | Simplex | 38229971 | Mei Sun et al. (2024) | |
c.314G>A | p.Cys105Tyr | splice_site_variant | De novo | - | - | 30679821 | Fountain MD , et al. (2019) | |
c.3174G>T | p.Arg1058= | splice_site_variant | De novo | - | - | 30679821 | Fountain MD , et al. (2019) | |
c.715C>T | p.Arg239Ter | stop_gained | Unknown | - | Unknown | 37849578 | Khaled N Itani et al. (2023) | |
c.1969C>G | p.Pro657Ala | missense_variant | De novo | - | Simplex | 25363768 | Iossifov I et al. (2014) | |
c.2244dup | p.Tyr749LeufsTer2 | frameshift_variant | De novo | - | - | 28333917 | Vissers LE , et al. (2017) | |
c.2140_2141del | p.Thr714Ter | frameshift_variant | De novo | - | - | 30679821 | Fountain MD , et al. (2019) | |
c.2196dup | p.Tyr733LeufsTer2 | frameshift_variant | De novo | - | - | 27479843 | Lelieveld SH et al. (2016) | |
c.1708dup | p.Glu570GlyfsTer19 | frameshift_variant | De novo | - | - | 30679821 | Fountain MD , et al. (2019) | |
c.247_250del | p.Glu83ArgfsTer18 | frameshift_variant | De novo | - | Simplex | 36466803 | Zheng H et al. (2022) | |
c.3305A>C | p.Asn1102Thr | missense_variant | Familial | Maternal | Extended multiplex | 38229971 | Mei Sun et al. (2024) |
Common Variants
No common variants reported.
SFARI Gene score
Strong Candidate, Syndromic
De novo variants (six multigenic deletions, one nonsense variant) affecting the USP7 gene were identified in seven patients presenting with developmental delay/intellectual disability, with five of these cases having an additional diagnosis of ASD (Hao et al., 2015). Subsequent statistical analysis determined that there was a strong correlation between the seven patients having both a de novo USP7 variant and the expressed phenotype that was likely not due to chance (p<0.0001). This gene was identified in Iossifov et al. 2015 as a strong candidate to be an ASD risk gene based on a combination of de novo mutational evidence and the absence or very low frequency of mutations in controls (PMID 26401017). Fountain et al., 2019 reported 16 newly identified individuals with de novo USP7 variants, obtained additional clinical information on the seven individuals previously identified in Hao et al., 2015, and found that the clinical phenotypes of these 23 individuals suggested a neurodevelopmental syndrome characterized by speech delay, developmental delay/intellectual disability, dysmorphic facial features, eye abnormalities, and behavioral problems, including ASD (9/17 cases, 53%) and ADHD (6/16 cases, 38%).
Score Delta: Score remained at 2S
criteria met
See SFARI Gene'scoring criteriaWe considered a rigorous statistical comparison between cases and controls, yielding genome-wide statistical significance, with independent replication, to be the strongest possible evidence for a gene. These criteria were relaxed slightly for category 2.
The syndromic category includes mutations that are associated with a substantial degree of increased risk and consistently linked to additional characteristics not required for an ASD diagnosis. If there is independent evidence implicating a gene in idiopathic ASD, it will be listed as "#S" (e.g., 2S, 3S, etc.). If there is no such independent evidence, the gene will be listed simply as "S."
10/1/2019
Score remained at 2S
New Scoring Scheme
Description
De novo variants (six multigenic deletions, one nonsense variant) affecting the USP7 gene were identified in seven patients presenting with developmental delay/intellectual disability, with five of these cases having an additional diagnosis of ASD (Hao et al., 2015). Subsequent statistical analysis determined that there was a strong correlation between the seven patients having both a de novo USP7 variant and the expressed phenotype that was likely not due to chance (p<0.0001). This gene was identified in Iossifov et al. 2015 as a strong candidate to be an ASD risk gene based on a combination of de novo mutational evidence and the absence or very low frequency of mutations in controls (PMID 26401017). Fountain et al., 2019 reported 16 newly identified individuals with de novo USP7 variants, obtained additional clinical information on the seven individuals previously identified in Hao et al., 2015, and found that the clinical phenotypes of these 23 individuals suggested a neurodevelopmental syndrome characterized by speech delay, developmental delay/intellectual disability, dysmorphic facial features, eye abnormalities, and behavioral problems, including ASD (9/17 cases, 53%) and ADHD (6/16 cases, 38%).
Reports Added
[New Scoring Scheme]1/1/2019
Score remained at 2S
Description
De novo variants (six multigenic deletions, one nonsense variant) affecting the USP7 gene were identified in seven patients presenting with developmental delay/intellectual disability, with five of these cases having an additional diagnosis of ASD (Hao et al., 2015). Subsequent statistical analysis determined that there was a strong correlation between the seven patients having both a de novo USP7 variant and the expressed phenotype that was likely not due to chance (p<0.0001). This gene was identified in Iossifov et al. 2015 as a strong candidate to be an ASD risk gene based on a combination of de novo mutational evidence and the absence or very low frequency of mutations in controls (PMID 26401017). Fountain et al., 2019 reported 16 newly identified individuals with de novo USP7 variants, obtained additional clinical information on the seven individuals previously identified in Hao et al., 2015, and found that the clinical phenotypes of these 23 individuals suggested a neurodevelopmental syndrome characterized by speech delay, developmental delay/intellectual disability, dysmorphic facial features, eye abnormalities, and behavioral problems, including ASD (9/17 cases, 53%) and ADHD (6/16 cases, 38%).
4/1/2017
Score remained at 2
Description
De novo variants (six multigenic deletions, one nonsense variant) affecting the USP7 gene were identified in seven patients presenting with developmental delay/intellectual disability, with five of these cases having an additional diagnosis of ASD (Hao et al., 2015). Subsequent statistical analysis determined that there was a strong correlation between the seven patients having both a de novo USP7 variant and the expressed phenotype that was likely not due to chance (p<0.0001). This gene was identified in Iossifov et al. 2015 as a strong candidate to be an ASD risk gene based on a combination of de novo mutational evidence and the absence or very low frequency of mutations in controls (PMID 26401017).
Reports Added
[USP7 Acts as a Molecular Rheostat to Promote WASH-Dependent Endosomal Protein Recycling and Is Mutated in a Human Neurodevelopmental Disorder.2015] [Low load for disruptive mutations in autism genes and their biased transmission.2015] [Synaptic, transcriptional and chromatin genes disrupted in autism.2014] [The contribution of de novo coding mutations to autism spectrum disorder2014] [Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability2016] [A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology.2017]7/1/2016
Score remained at 2
Description
De novo variants (six multigenic deletions, one nonsense variant) affecting the USP7 gene were identified in seven patients presenting with developmental delay/intellectual disability, with five of these cases having an additional diagnosis of ASD (Hao et al., 2015). Subsequent statistical analysis determined that there was a strong correlation between the seven patients having both a de novo USP7 variant and the expressed phenotype that was likely not due to chance (p<0.0001). This gene was identified in Iossifov et al. 2015 as a strong candidate to be an ASD risk gene based on a combination of de novo mutational evidence and the absence or very low frequency of mutations in controls (PMID 26401017).
10/1/2015
Increased from to 2
Description
De novo variants (six multigenic deletions, one nonsense variant) affecting the USP7 gene were identified in seven patients presenting with developmental delay/intellectual disability, with five of these cases having an additional diagnosis of ASD (Hao et al., 2015). Subsequent statistical analysis determined that there was a strong correlation between the seven patients having both a de novo USP7 variant and the expressed phenotype that was likely not due to chance (p<0.0001). This gene was identified in Iossifov et al. 2015 as a strong candidate to be an ASD risk gene based on a combination of de novo mutational evidence and the absence or very low frequency of mutations in controls (PMID 26401017).
Krishnan Probability Score
Score 0.56845914221644
Ranking 1115/25841 scored genes
[Show Scoring Methodology]
ExAC Score
Score 0.99999999841186
Ranking 107/18225 scored genes
[Show Scoring Methodology]
Iossifov Probability Score
Score 0.933
Ranking 106/239 scored genes
[Show Scoring Methodology]
Sanders TADA Score
Score 0.94240824810298
Ranking 15295/18665 scored genes
[Show Scoring Methodology]
Zhang D Score
Score 0.34919320753624
Ranking 2019/20870 scored genes
[Show Scoring Methodology]
Interactome
- Protein Binding
- DNA Binding
- RNA Binding
- Protein Modification
- Direct Regulation
- ASD-Linked Genes
Interaction Table
Interactor Symbol | Interactor Name | Interactor Organism | Interactor Type | Entrez ID | Uniprot ID |
---|---|---|---|---|---|
ACD | Adrenocortical dysplasia protein homolog | Human | Protein Binding | 65057 | Q96AP0 |
ARHGEF6 | Rho guanine nucleotide exchange factor 6 | Human | Protein Binding | 9459 | Q15052-2 |
ARL6IP4 | ADP-ribosylation factor-like protein 6-interacting protein 4 | Human | Protein Binding | 51329 | Q66PJ3-2 |
C14ORF179 | Intraflagellar transport protein 43 homolog | Human | Protein Binding | 112752 | Q96FT9-2 |
FAM170A | Protein FAM170A | Human | Protein Binding | 340069 | A1A519-2 |
PHF7 | PHD finger protein 7 | Human | Protein Binding | 51533 | Q9BWX1 |
POTEB | POTE ankyrin domain family member B | Human | Protein Binding | 102724631 | Q6S5H4 |
POTEC | POTE ankyrin domain family member C | Human | Protein Binding | 388468 | B2RU33-2 |